John F. Paolini - Apr 7, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol: KNSA
Transactions as of: Apr 7, 2025
Transactions value $: -$14,886
Form type: 4
Date filed: 4/9/2025, 04:43 PM
Previous filing: Apr 3, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Ordinary Share	Options Exercise		+2.5K	+4.49%		58.1K	Apr 7, 2025	Direct	F1
transaction	KNSA	Class A Ordinary Share	Tax liability	-$14.9K	-734	-1.26%	$20.28	57.4K	Apr 7, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-2.5K	-50.01%	$0.00	2.5K	Apr 7, 2025	Class A Ordinary Share	2.5K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.